Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-University of Munich, Butenandtstraße 5, 81377 Munich, Germany.
J Control Release. 2022 May;345:549-556. doi: 10.1016/j.jconrel.2022.03.039. Epub 2022 Mar 28.
The coronavirus pandemic has changed our perception of RNA medicines, and RNA vaccines have revolutionized our pandemic preparedness. But are we indeed prepared for the next variant or the next emerging virus? How can we prepare? And what does the role of inhaled antiviral RNA play in this regard? When the pandemic started, I rerouted much of the ongoing inhaled RNA delivery research in my group towards the inhibition and treatment of respiratory viral infections. Two years later, I have taken the literature, past and ongoing clinical trials into consideration and have gained new insights based on our collaborative research which I will discuss in this oration.
冠状病毒大流行改变了我们对 RNA 药物的看法，RNA 疫苗也彻底改变了我们应对大流行的准备工作。但是，我们是否真的为下一个变种或下一个新兴病毒做好了准备？我们如何做好准备？吸入式抗病毒 RNA 在这方面发挥什么作用？大流行开始时，我将小组正在进行的大部分吸入式 RNA 递药研究重新调整为针对呼吸道病毒感染的抑制和治疗。两年后，我考虑了文献、过去和正在进行的临床试验，并根据我们的合作研究获得了新的见解，我将在本次演讲中进行讨论。
